CHAMPIONS ONCOLOGY, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $6.25 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-07-31 was $6.25M.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-07-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-04-30 was $0.00, a 100.00% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-01-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $231.00K, a 12.68% increase from fiscal 2022.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $205.00K, a 96.65% decline from fiscal 2021.
- CHAMPIONS ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $6.12M, a 91.22% increase from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-07-31 | $6.25M 10-Q · filed 2026-09-11 | |||
| 2025-07-31 | $0.00 10-Q · filed 2026-09-11 | |||
| 2024-04-30 | $0.00 10-K · filed 2024-07-19 | |||
| 2023-04-30 | $231.00K 10-K · filed 2024-07-19 | |||
| 2022-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-24 | $0.00 derived: sum of 2 quarters · filed 2023-07-24 | $205.00K derived: sum of 3 quarters · filed 2023-07-24 | $205.00K 10-K · filed 2023-07-24 |
| 2022-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | $205.00K derived: sum of 2 quarters · filed 2022-03-15 | $205.00K 10-Q · filed 2022-03-15 | $2.45M derived: sum of 4 quarters · filed 2022-07-22 |
| 2021-10-31 | $205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | $205.00K 10-Q · filed 2021-12-13 | $2.45M derived: sum of 3 quarters · filed 2022-07-22 | $2.45M derived: sum of 4 quarters · filed 2022-07-22 |
| 2021-07-31 | $0.00 10-Q · filed 2021-09-13 | $2.25M derived: sum of 2 quarters · filed 2022-07-22 | $2.25M derived: sum of 3 quarters · filed 2022-07-22 | $2.25M derived: sum of 4 quarters · filed 2022-07-22 |
| 2021-04-30 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-22 | $2.25M derived: sum of 2 quarters · filed 2022-07-22 | $2.25M derived: sum of 3 quarters · filed 2022-07-22 | $6.12M 10-K · filed 2022-07-22 |
| 2021-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $3.87M 10-Q · filed 2022-03-15 | $3.87M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | $3.87M 10-Q · filed 2021-12-13 | $3.87M derived: sum of 3 quarters · filed 2021-12-13 | $3.87M derived: sum of 4 quarters · filed 2021-12-13 |
| 2020-07-31 | $3.87M 10-Q · filed 2021-09-13 | $3.87M derived: sum of 2 quarters · filed 2021-09-13 | $3.87M derived: sum of 3 quarters · filed 2021-09-13 | $3.87M derived: sum of 4 quarters · filed 2021-09-13 |
| 2020-04-30 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-07-26 | -$4.00K derived: sum of 2 quarters · filed 2021-07-26 | -$4.00K derived: sum of 3 quarters · filed 2021-07-26 | $3.20M 10-K · filed 2021-07-26 |
| 2020-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-03-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-15 | $3.21M 10-Q · filed 2021-03-15 | |
| 2019-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-12-14 | $3.21M 10-Q · filed 2020-12-14 | ||
| 2019-07-31 | $3.21M 10-Q · filed 2020-09-14 | |||
| 2019-04-30 | $0.00 10-K · filed 2020-07-28 | |||
| 2018-07-31 | $0.00 10-Q · filed 2019-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |